September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School of Medicine, recently discussed the rationale and design of the first clinical trial combining Theraclion’s Echotherapy with the checkpoint inhibitor pembrolizumab in women with metastatic breast cancer.

Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. The new approach utilizes a single molecule designed to bind two proteins with differing affinities in an effort to optimize specific tumor localization — prostate-specific membrane antigen (PSMA) and human serum albumin — thereby enhancing tumor localization for targeted alpha radionuclide therapy. The study is presented in the featured basic article of the September issue of The Journal of Nuclear Medicine.

The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease which can result in the loss of a limb. To help minimize amputations among their patient population, Capel Surgical Clinic & Vascular Center in Greenwood, Miss., uses advanced X-ray technology to restore blood flow in occluded arteries. Capel Surgical Clinic also uses the Ultimax-i FPD multipurpose system from Toshiba Medical, a Canon Group company, for interventional procedures, diagnostic angiograms and aortagrams.